ascopubs.org5d
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...
ascopubs.org5d
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...
ascopubs.org5d
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
ascopubs.org5d
A survival prediction model for veterans with advanced bladder cancer (BC) treated with immune checkpoint inhibitors (ICI).
Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer. PPARG protein expression in advanced urothelial carcinoma and selection for response to FX-909, a first-in-class PPARG-targeting ...
ascopubs.org5d
Analysis of gene expression signatures in prostate cancer prior to liver metastases.
Impact of homologous recombination repair alterations (HRRalt) on survival outcomes of patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Effects of emerin dysregulation on the ...
ascopubs.org3d
Addressing the Oncologist Shortage in Latin America: Insights From a Survey of Medical Oncology Fellowship Programs
Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort In total, 232 fellowship programs exist in the surveyed nations, ...
ascopubs.org5d
Evaluating the spectrum of disease within Gleason grade group 3: Results from a large institutional cohort.
The nature of progression on long term active surveillance for confirmed Gleason grade group 1 prostate cancer in the modern era. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...
ascopubs.org5d
Real-world prevalence and outcomes of androgen receptor ligand-binding domain mutations in prostate cancer.
Real-world evidence for factors associated with development of castration-resistant prostate cancer (CRPC). Evaluating the association between bone pain and radiologic progression-free survival (rPFS) ...
ascopubs.org4d
Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer.
DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.
ascopubs.org10d
Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
ascopubs.org5d
Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines.
Deciphering immune-genomic markers of hyperprogression in patients (Pts) with metastatic urothelial cancer (mUC) treated with immune checkpoint inhibitors (ICIs). This is an ASCO Meeting Abstract from ...
ascopubs.org5d
Survival in advanced prostate cancer (PCa) patients with visceral metastasis: A population-based SEER study.
Impact of androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy on health-related quality of life.